

•MOMETASONE 50 MCG NASAL SPRAY

Class: Corticosteroid, Nasal.

Indications:

Treatment of nasal symptoms of seasonal and perennial allergic rhinitis; prevention of nasal symptoms associated with seasonal allergic rhinitis; treatment of nasal polyps in adults.

Available dosage form in the hospital:

- MOMETASONE 50 MCG NASAL SPRAY

Dosage:

-Seasonal and perennial allergic rhinitis: Intranasal:

-U.S. labeling:

-Treatment: 2 sprays (100 mcg) in each nostril once daily

-Prevention: 2 sprays (100 mcg) in each nostril once daily beginning 2-4 weeks prior to pollen season.

-Canadian labeling (not in U.S. labeling): Initial: 2 sprays (100 mcg) in each nostril once daily; upon symptom control, may consider dose reduction to 1 spray (50 mcg) in each nostril once daily as maintenance therapy. **Note:** If adequate symptom control is not achieved with initial dosing, may increase dose to 4 sprays (200 mcg) in each nostril once daily (total daily dose: 400 mcg). Dose reduction is recommended upon symptom control.

-Treatment of nasal polyps: Intranasal: 2 sprays (100 mcg) in each nostril twice daily; 2 sprays (100 mcg) once daily may be effective in some patients

-Rhinosinusitis, adjunctive treatment (acute): Intranasal: Canadian labeling (not in U.S. labeling): 2 sprays (100 mcg) in each nostril twice daily; if inadequate symptom control, may increase to 4 sprays (200 mcg) in each nostril twice daily (total daily dose: 800 mcg)

-Rhinosinusitis treatment (acute, mild-to-moderate, uncomplicated): Intranasal: Canadian labeling (not in U.S. labeling): 2 sprays (100 mcg) in each nostril twice daily; use beyond 15 days has not been studied.

Geriatric

Refer to adult dosing.

Common side effect:

Central nervous system: Headache (17% to 26%)

Respiratory: Pharyngitis (8% to 13%), cough (nasal inhalation 7% to 13%), epistaxis (1% to 11%)

Miscellaneous: Viral infection (nasal inhalation 8% to 14%).

Pregnancy Risk Factor: C.